Headquartered in 124 Dvora Hanevi?a St., Tel Aviv-yafo·Fiscal year ends December·NYSE: TEVA·tevapharm.com
About Teva
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company shifting toward innovative biopharmaceuticals under its Pivot to Growth strategy, backed by a large generics business.
**Innovative medicines.** Its portfolio focuses on neuroscience and immunology:
- AUSTEDO/AUSTEDO XR (deutetrabenazine) for tardive dyskinesia and Huntington's chorea.
- AJOVY (fremanezumab) for migraine prevention.
- UZEDY (risperidone LAI) for schizophrenia.
- WELTRUZA (olanzapine LAI), approved by the FDA in October 2026.
- Legacy brands COPAXONE and BENDEKA/TREANDA.
**Pipeline.** Late-stage assets include:
- Ecopipam for pediatric Tourette syndrome (NDA under FDA review).
- BXCL-501, acquired from BioXcel.
- Anti-IL-15 (TEV-'408) for celiac disease and vitiligo.
- Duvakitug (anti-TL1A), which generated development milestone payments.
**Generics and biosimilars.** Teva sells complex generics, OTC products and biosimilars, including TRUXIMA, SIMLANDI and DEGEVMA, and is expanding through partnerships such as Samsung Bioepis.
**Reporting structure.**
- Segments: United States, Europe, and International Markets (more than 35 countries, including Canada, Israel, Russia and Latin America).
- Other Activities: the Anda U.S. distribution business, third-party API sales (being divested), the Medis out-licensing platform, and contract manufacturing.
Teva's ordinary shares are listed directly on the NYSE and TASE. It regained an investment grade credit rating in 2026, and had total debt of $16.7 billion and net debt of $12.6 billion as of September 30, 2026. Updated
43 stocks notched fresh 52-week highs this week, with leadership spread across Motorola Solutions, ICICI Bank, Edwards Lifesciences, Coca-Cola, Humana and Fastenal. Motorola Solutions leads at $530.42, 7.7% past its prior peak.
Cramer says Nvidia leadership turmoil has made him gun shy on tech, yet writing off data center names risks big upside
CoreWeave CEO: compute demand 10 times oversubscribed for 2027, with chips recontracting at 20% to 50% premiums
Cramer would rather own Colgate or Johnson & Johnson than chase the noise right now
Caller questions on Darden's Olive Garden value proposition, Meta re-entry, and Jersey Mike's under Charlie Morrison
The tell is that four-year-old GPUs are being recontracted above their original prices, which undercuts the view that AI hardware depreciates into worthlessness. Cramer is keeping data center exposure in semis, networking, turbines and cooling even while trimming elsewhere, and he is leaning defensive with staples and pharma as the Nvidia story gets messier.
Now director at TEVA PHARMACEUTICAL INDUSTRIES LTD
Healthcare policy veteran David J. Brailer, the first U.S. National Coordinator for Health IT and a longtime Health Evolution investor, now sits inside the boardroom at the $50.9 billion generics maker. His first Form 3 starts the clock on every future buy or sell he makes, and boards rarely add that kind of policy firepower without a strategy shift in mind.
Teva's $42.99 close tops the high it set three sessions earlier by 0.89%, capping a climb from $24.26 a year ago. The generic drugmaker is now held by 40 ETFs, so the grind higher is lifting broad funds too.
Teva's innovative brands AUSTEDO, AJOVY and UZEDY grew 33% in local currency, offsetting the lenalidomide-driven slide in U.S. generics revenue. Both lines came in ahead of expectations, and management raised full-year revenue guidance to $16.7 to $17.0 billion.
Pre-Market Stock Futures: Futures are trading higher after a rough week in which sellers moved hard against the big tech companies, which reported mostly solid results. Still, massive spending on AI, free…
Pre-Market Stock Futures: Futures are trading higher after the bulls charged early Wednesday after the August CPE inflation report came in better than expected. But by the close, the tech-heavy Nasdaq was…
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning. He has been piling into Natera (NASDAQ:NTRA | NTRA Price Prediction),…
Pfizer (NYSE: PFE | PFE Price Prediction) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing after its COVID…
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing. He’s now piling into Natera (NASDAQ:NTRA | NTRA Price…
Billionaire investment legend Stanley Druckenmiller is quickly becoming one of my favorite big-money managers to follow quarter to quarter. He’s not just limiting himself to value stocks, but has shown a knack…
If you’re looking for solid opportunities, keep an eye on 13F filings. Most times, they offer an under-the-hood look at which stocks some of the most successful asset managers and billionaires were…
Friday's top analyst upgrades and downgrades included American Express, Aptiv, BorgWarner, First Horizon, Keurig Dr Pepper, Meta Platforms, MGIC Investment, Simon Property Group and Teva Pharmaceutical Industries.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Friday's top analyst upgrades and downgrades included Alcoa, Charles Schwab, Cognizant Technology Solutions, IBM, Newmont, Okta, Philip Morris International, Roblox, Shopify, Teva Pharmaceutical Industries, Texas Instruments and Transocean.
Monday’s additional top analyst upgrades and downgrades were on ASML, Bank of America, Dominion Energy, Hasbro, Nio, Occidental Petroleum, Teva Pharmaceutical Industries and more.
Friday's top analyst upgrades and downgrades included AT&T, Exxon Mobil, Hasbro, Juniper Networks, Moderna, Palo Alto Networks, Snap, Teva Pharmaceutical, Under Armour and Zscaler.
Friday's additional top analyst upgrades and downgrades included Acadia Pharmaceuticals, BioCryst Pharmaceuticals, Duke Energy, Kellogg, Paramount Global, Rhythm Pharmaceuticals and Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company shifting toward innovative biopharmaceuticals under its Pivot to Growth strategy, backed by a large generics business. **Innovative medicines.** Its portfolio focuses on neuroscience and immunology: - AUSTEDO/AUSTEDO XR (deutetrabenazine) for…
What is the TEVA stock price target?
24/7 Wall St.'s 12-month price target for TEVA is $52.21, rated Buy. The Wall Street consensus target is $50.51. TEVA price prediction →